“Dasatinib Tyrosine Kinase Inhibitor As Second and Third Line Therapy in Chronic Myeloid Leukemia: Outcome of a Nepalese Study”. Journal of Patan Academy of Health Sciences 5, no. 1 (June 29, 2018): 47–56. Accessed July 9, 2026. https://nepjol.info/index.php/JPAHS/article/view/24042.